Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza A H3N2 vaccine
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
An influenza A H3N2 vaccine is a biological preparation designed to provide active acquired immunity against the H3N2 subtype of the influenza A virus. H3N2 is a major cause of seasonal influenza and is known for its high rate of antigenic drift, necessitating frequent updates to vaccine strains. These vaccines typically target the hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins of the virus. While most seasonal vaccines are quadrivalent (containing H1N1, H3N2, and two B strains), monovalent H3N2 vaccines are often used in clinical research to evaluate immunogenicity against specific emerging strains or as part of pandemic preparedness strategies. Modalities include inactivated virus, live-attenuated virus, recombinant proteins, and more recently, mRNA-based platforms.
- Other names
- H3N2 vaccineH-3N2 vaccineH 3N2 vaccineA/H3N2 vaccineinfluenza A virus subtype H3N2 vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on influenza A H3N2 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza A H3N2 vaccine.